Quarterly ResultMay 14, 2026, 04:13 PM
Jasper Therapeutics Warns of Going Concern; Q1 Net Loss Narrows to $1.2M
AI Summary
Jasper Therapeutics, a clinical-stage biotechnology company, reported a significantly reduced net loss of $1.2 million for Q1 2026, down from $21.2 million in Q1 2025. This improvement was primarily driven by a $9.6 million non-cash gain from the change in fair value of warrant liability and reduced operating expenses. However, the company issued a going concern warning, stating that its $14.1 million cash and cash equivalents as of March 31, 2026, are insufficient to fund operations for the next twelve months, and it is actively seeking additional capital.
Key Highlights
- Jasper Therapeutics issued a going concern warning due to insufficient cash for 12 months.
- Q1 2026 net loss significantly narrowed to $1.2 million from $21.2 million in Q1 2025.
- Cash and cash equivalents decreased to $14.1 million as of March 31, 2026, from $28.7 million at Dec 31, 2025.
- Research and development expenses decreased to $5.8 million in Q1 2026 from $16.2 million in Q1 2025.
- Total operating expenses fell to $11.0 million in Q1 2026 from $21.8 million in Q1 2025.
- Net cash used in operating activities improved to $14.5 million in Q1 2026 from $22.8 million in Q1 2025.
- A non-cash gain of $9.6 million from warrant liability revaluation contributed to the reduced net loss.